Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Sep;76(3):455-66.
doi: 10.1111/bcp.12075.

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Wolfgang Mueck  1 , Dagmar Kubitza, Michael Becka
Affiliations
Clinical Trial

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Wolfgang Mueck et al. Br J Clin Pharmacol. 2013 Sep.

Abstract

Aims: The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve cytochrome P450 3A4 (CYP3A4) and 2J2 (CYP2J2), CYP-independent mechanisms, and P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) (ABCG2).

Methods: The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on rivaroxaban were studied in healthy volunteers.

Results: Rivaroxaban did not interact with midazolam (CYP3A4 probe substrate). Exposure to rivaroxaban when co-administered with midazolam was slightly decreased by 11% (95% confidence interval [CI] -28%, 7%) compared with rivaroxaban alone. The following drugs moderately affected rivaroxaban exposure, but not to a clinically relevant extent: erythromycin (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), clarithromycin (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% CI 44%, 64%]) and fluconazole (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% increase [95% CI 29%, 56%]). A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).

Conclusions: Results suggest that rivaroxaban may be co-administered with CYP3A4 and/or P-gp substrates/moderate inhibitors, but not with strong combined CYP3A4, P-gp and Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.

Keywords: P-glycoprotein; cytochrome P450; drug interactions; healthy subjects; rivaroxaban.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma concentration–time profile of rivaroxaban (20 mg [fluconazole study] or 10 mg [all other studies] once daily) in the absence and presence of (A) steady-state ketoconazole (400 mg once daily given concomitantly for 5 days), formula image, rivaroxaban alone (n = 20); formula image, rivaroxaban + ketoconazole (n = 20); (B) steady-state ritonavir (600 mg twice daily for 8 days), formula image, rivaroxaban alone (n = 12); formula image, rivaroxaban + ritonavir (n = 12); (C) steady-state clarithromycin (500 mg twice daily for 4 days), formula image, rivaroxaban alone (n = 15); formula image, rivaroxaban + clarithromycin (n = 15); (D) steady-state erythromycin (500 mg three times daily for 5 days), formula image, rivaroxaban alone (n = 15); formula image, rivaroxaban + erythromycin (n = 15); (E) steady-state fluconazole (400 mg once daily for 6 days), formula image, rivaroxaban alone (n = 13); formula image, rivaroxaban + fluconazole (n = 13)
Figure 2
Figure 2
Metabolic clearance and elimination pathways of rivaroxaban based on in vitro investigations [–18] and human studies [12, 13]. All numbers are approximate. aPotentially not absorbed
See this image and copyright information in PMC

References

    1. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–521. - PubMed
    1. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5:886–888. - PubMed
    1. Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor. Thromb Haemost. 2007;97:471–477. - PubMed
    1. Perzborn E, Arndt B, Harwardt M, Lange U, Fischer E, Trabant A. Antithrombotic efficacy of BAY 59-7939 – an oral, direct Factor Xa inhibitor – compared with fondaparinux in animal arterial thrombosis and thromboembolic death models. Eur Heart J. 2005;26(Suppl):Abstract P2943.
    1. Turpie AGG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011;105:444–453. - PubMed

Publication types

MeSH terms